Business highlights * Cx601: Phase III trial in Europe on track to deliver clinical results in third quarter of 2015 * Cx601: paediatric investigation plan accepted by European Medicines Agency * Cx601: US advisory board appointed * Cx611: Phase I trial in healthy volunteers approved by Dutch regulatory authority * Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation appointed Financial highlights * Liquidity position of Euro 17.7 million "In the third quarter of this year, TiGenix has continued to prepare its most advanced product candidate for market readiness and commercialisation," said Eduardo Bravo, CEO of TiGenix.
http://ift.tt/1DYrV4t
http://ift.tt/1DYrV4t
No comments:
Post a Comment